- Home
- PRQR vs CEE Comparison
PRQR vs CEE Comparison
Compare PRQR & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRQR | CEE |
|---|---|---|
| Founded | 2012 | N/A |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 166.5M | 136.4M |
| IPO Year | 2014 | 1994 |
Fundamental Metrics
Financial Performance| Metric | PRQR | CEE |
|---|---|---|
| Price | $1.53 | $21.12 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.25 | N/A |
| AVG Volume (30 Days) | ★ 710.7K | 21.0K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.92 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $14.25 |
| 52 Week High | $3.10 | $21.98 |
Technical Indicators
Market Signals| Indicator | PRQR | CEE |
|---|---|---|
| Relative Strength Index (RSI) | 42.73 | 58.16 |
| Support Level | $1.51 | $14.91 |
| Resistance Level | $1.58 | $21.86 |
| Average True Range (ATR) | 0.12 | 0.77 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 31.67 | 65.31 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.